Form 4: Galectin Therapeutics Director Acquires 60,000 Stock Options

Benjamin Carson Sr., a director at Galectin Therapeutics, acquired 60,000 stock options on January 23, 2025, under the company's 2019 Omnibus Equity Incentive Plan.

Summary

• Benjamin Carson Sr., a director of Galectin Therapeutics, acquired 60,000 stock options on January 23, 2025.
• These options were granted under the company's 2019 Omnibus Equity Incentive Plan.
• The exercise price for these options is $1.23 per share.
• The options will vest 100% on December 31, 2025.
• The options expire on January 23, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction, indicating a positive alignment of interests between the director and the company, but it is not a major event.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Industry Context

This is a standard transaction for a director of a publicly traded company, often used as part of compensation and incentive programs.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology sector.
• The vesting schedule of 100% on December 31, 2025, is a typical vesting period for such grants.
• The 10-year expiration period is also standard for stock options.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, as the value of the options is tied to the company's stock performance.

Key Dates

Keywords

stock options, equity incentive plan, director, insider trading, Galectin Therapeutics, GALT